Pipeline Therapeutics to Participate in Multiple Upcoming Investor Conferences

2023-09-07

交易

引进/卖出临床1期

SAN DIEGO--(BUSINESS WIRE)-- Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023, NY, NY: Pipeline management will participate in 1x1s with investors during the conference. UBS Biotechnology Private Company Virtual Symposium, September 20-21, 2023: Carmine Stengone, Pipeline’s CEO, will participate in a fireside chat on Thursday, September 21, 2023, at 10:30am ET. Pipeline management will also participate in 1x1s with investors during the conference. About Pipeline Therapeutics Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in central nervous system disorders. The Company’s lead wholly-owned program, PIPE-791, an LPA1 receptor antagonist LPA1 receptor antagonist, is advancing through Phase 1 testing to support treatment of neurological diseases. For more information, please visit and engage with us on LinkedIn.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构